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Formulation of FDT (fast dispersing tablets) of nebivolol was optimized and evaluated using simplex 
lattice design (SLD). The influence of type and concentration of three disintegrants viz., Ac-Di-Sol, 
Primojel and Polyplasdone XL on hardness, friability and disintegration time of tablet was studied. 
Response surface plot and the polynomial equations were used to evaluate influence of polymer on 
the tablet properties. Results were statistically analyzed using ANOVA, and a p < 0.05 was considered 
statistically significant. Results reveal that fibrous integrity and optimal degree of substitution in Primojel 
and Ac-Di-Sol are mainly responsible for the hardness of the tablet. Use of Polyplasdone in higher 
percentage in tablet formulation may result in high friability. Increase in concentration of Ac-Di-Sol 
increases the disintegration time but increased concentration of Primojel in the tablet formulation decreases 
the disintegration time. This is also evident from model terms for disintegration time with a high ‘F’ 
value of 14.69 and ‘p’ value of 0.0031 (<0.05). The reason could be that Primojel has higher swelling 
properties and an optimum hydration capacity, which favors fast disintegration of a tablet. In conclusion, 
careful selection of disintegrant for FDT could improve their properties. Use of Simplex Lattice Design 
for formulation development could simplify the formulation process and reduce the production cost.
Uniterms: Nebivolol/fast dispersing tablets. Simplex lattice design. Tablets/fast dispersing/swelling 
capacity. Tablets/fast dispersing/hydration capacity. Tablets/fast dispersing/disintegration time.
Otimizou-se e avaliou-se formulação de comprimidos de dispersão rápida (CDR) de nebivolol, 
usando planejamento de grade simplex (PGS). Estudou-se a influência do tipo e da concentração de 
três desintegrantes viz, Ac-Di–Sol, Primojel e Poliplasdona XL, na dureza, friabilidade e tempo de 
desintegração do comprimido. O gráfico de superfície de resposta e as equações polinomiais foram 
utilizados para avaliar a influência do polímero nas propriedades do comprimido. Os resultados foram 
analisados estatisticamente por ANOVA, considerando-se p < 0,05 como estatisticamente significativo. 
Os resultados revelam que a integridade das fibras e o grau de substituição ótimo no Primojel e Ac-
Di-Sol são os principais responsáveis pela dureza do comprimido. O uso de Poliplasdona em maior 
porcentagem na formulação pode produzir friabilidade elevada. O aumento de Ac-Di-Sol aumenta o 
tempo de desintegração, mas o aumento da concentração de Primojel na formulação diminui o tempo 
de desintegração. Isto é, também, evidente no modelo de tempo de desintegração com alto valor de “F” 
de 14,69 e “p” de 0,0031 (< 0,05). A razão poderia ser que o Primojel tem maiores propriedades de 
intumescimento e ótima capacidade de hidratação, favorecendo a desintegração rápida do comprimido. 
Em conclusão, a cuidadosa seleção de um desintegrante para CDR poderia aprimorar suas propriedades. 
O uso do PGS para o desenvolvimento da formulação poderia simplificar o processo de formulação e 
reduzir o custo de produção.
Unitermos: Nebivolol/comprimidos de dispersão rápida. Planejamento de grade simplex. Comprimidos 
de dispersão rápida/capacidade de intumescimento. Comprimidos de dispersão rápida/capacidade de 
hidratação. Comprimidos de dispersão rápida/tempo de decomposição.
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INTRODUCTION
Nebivolol is a selective beta-1 receptor antagonist 
used for the management of hypertension and angina pain. 
It reaches mean peak plasma concentration approximately 
in 1.5 to 4 h post oral administrations (Na, Larry, 2002). 
In such cases it is very essential to enhance onset of action 
of a drug.Therefore, in this work the goal has been set to 
formulate and evaluate fast dispersing tablets (FDT) of 
nebivolol. FDT improve bioavailability of drugs by rapid 
disintegration/dissolution/dispersion in oral cavity and by 
pregastric absorption of dispersed drugs that pass down 
into the stomach. The amount of drug which is subjected 
to first pass metabolism is also reduced from FDT as 
compared to conventional tablet(Tansel et al., 2011; Shery, 
Arun, Anroop, 2009). Super disintegrant is the principle 
ingredient of the FDT to accommodate rapid disintegration 
time of the formulation. Efficiency of the formulation is 
varied according to the type and proportion of disintigrant 
in it (Deshika,Viness, Yahya, 2009; Alvaro,Consuelo, 
Ramón, 2011), since each disintegrant works on several 
unique properties, such as swelling properties (Zhao, Larry, 
Augsburger,2005), hydration capacity(Seonget al.,2008), 
among others. These properties in turn depend upon the 
basic nature of the polymer chain (Zhao, Larry, Augsburger, 
2005), degree of cross linking (Bi Yet al., 1996) and type of 
cross linking (Gohel et al., 2004; Rashid et al., 2008) along 
the polymer chain. Hence, selection of an ideal disintegrant 
for the formulation is a real challenging work. Three super 
disintegrants viz., Ac-Di-Sol (Cross-linked carboxymethyl 
cellulose), Primojel (sodium salt of carboxymethyl ether 
of starch) and Polyplasdone XL (Cross-linked poly vinyl 
pyrrolidone) were tested individually and in combination. 
The experiment was executed using simplex lattice design 
(SLD) in order to simplify the formulation procedure and 
to optimize the formulation with limited number of trials 
(Zhou et al.,2011). SLD is useful when the trial - error 
approach may not be possible for the formulation design 
and the relationship between influential factors and output 
response in the work is complex.
MATERIAL AND METHODS 
Material
Nebivolol HCl(Sanofi Aventis Pharma, Ltd, India) 
was received as a gift sample. Ac-Di-Sol, Primojel, 
Polyplasdone XL, (Loba chem. Pvt. Ltd. Mumbai) 
microcrystalline cellulose (MCC) and mannitol (Sisco 
Research Laboratories Pvt. Ltd) were purchased. All 
other chemicals used in the study were of analytical grade. 
Stat-ease Design-Expert® software is used to design the 
formulation.
Compatibility studies
Drug-excipient interactions were checked by 
performing FTIR study of nebivolol alone and its physical 
mixture with Ac-Di-Sol, Primojel and Polyplasdone XL on 
Bruker optics, Germany Model: Tensor 27. The scanning 
range was 400 to 4000 cm-1 and the resolution was 4 cm-1, 
represented as % transmittance versus wave number.
Simplex lattice design and statistical analysis
Simplex lattice design was adopted to optimize the 
formulation variables. Three dependent variables viz, 
hardness (kg/cm2), friability (%) and disintegration time 
(sec) were evaluated by changing the concentrations of 
disintegrants (independent variables) viz; Polyplasdone 
XL (A), Ac-Di-Sol (B) and Primojel (C). Ten batches 
(F1-F10) of FDTs were prepared, considering one at each 
vertex (A, B, C), one each at the halfway point between 
vertices (AB, BC, and AC), one at the center point (ABC) 
and one each at the corner of the vertex (ABC, BAC, CAB) 
as shown in Figure 1. Each vertex represents a formulation 
containing the maximum amount of 1 component, with 
the other 2 components at a minimum level. The halfway 
point between the 2 vertices and at corner represents a 
formulation containing the average of the minimum and 
maximum amounts of the 3 ingredients. The center point 
represents a formulation containing one third of each 
ingredient (Tadashi et al., 2011; Shirsand et al.,2010).
FIGURE 1 - Simplex lattice design for 3 components (A, B and 
C) system.
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TABLE I - Simplex lattice design for formulation
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
Nebivolol HCl* 5 5 5 5 5 5 5 5 5 5
Primojel * 11 0 0 3.6 6 2.5 2.5 5.5 5.5 0
Polyplasdone XL* 0 11 0 3.6 2.5 6 2.5 5.5 0 5.5
Ac-Di-Sol* 0 0 11 3.6 2.5 2.5 6 0 5.5 5.5
Mannitol* 105 105 105 105 105 105 105 105 105 105
Magnesium stearate* 2 2 2 2 2 2 2 2 2 2
Talc* 1 1 1 1 1 1 1 1 1 1
Vanillin* 1 1 1 1 1 1 1 1 1 1
MCC Q.S* 150 150 150 150 150 150 150 150 150 150
Factors and corresponding level of disintegrant in the formulation
Variable levels in coded form (Factor) 0.000 0.227 0.333 0.500 0.545 1
Actual disintegrant level (mg) 0 2.5 3.6 5.5 6 11
*All Quantities are in mg
Analysis of variance (ANOVA) was performed to 
identify insignificant factors. The significance test for 
regression coefficients was checked using Student ‘t’test. 
Coefficient is significant if the calculated ‘t’value is greater 
than the critical value of‘t’(<0.05) (Gohel et al.,2007a).
Formulation development
The raw materials (Table I) of the formulation were 
passed through a #80 screen in dry state prior to mixing. 
Known quantities of drug, disintegrants, MCC and 
mannitol were weighed and mixed for the period of 10 
min in a mortar. This powder mixture was lubricated with 
magnesium stearate, talc and then finally with vanillin. 
The lubricated powder was compressed into tablets with 
10-station Rimek Minipress RSB-1 tablet punching 
machine using 7 mm concave punches. The dimensional 
specifications were measured using thickness gauge 
(Okimoto). Hardness of the tablet was measured using 
Monsanto hardness tester.
Drug content estimation
Standard calibration curve of nebivolol was 
constructed using UV-Visible spectrophotometer 
(Shimadzu-1700, Kyoto, Japan). Drug solution was 
prepared in 0.1 N HCl at the concentration range from 4 
to 60 µg/mL, sonicated, filtered using 0.45 µ (Millipore) 
membrane filter. The drug content of standard drug solution 
and tablet formulation was measured at 281 nm against 
0.1 N HCl as a blank solution (Lakshmana,Rajeswari, 
Sankar, 2010). This method was found to have good 
repeatability, reproducibility and relative standard 
deviation (RSD) was not more than 2%. The working 
curve equation was Y=0.016x with correlation coefficient 
value, r2 = 0.999.
Friability test
Roche friabilator was used for testing the friability 
of all the batches of tablet formulation. Twenty tablets 
were weighed accurately and placed in the tumbling 
apparatus that revolves at 25 rpm. After 4 min the tablets 
were weighed and the percentage loss in tablet weight 
was determined.
% Friability = [Initial weight - Final weight / Initial 
weight] x 100  (2)
Disintegration test
Disintegration test was performed for six tablets 
selected randomly from each batch. USP disintegration 
apparatus without disc consisting 900 mL of simulated 
salivary fluid (pH 6.4, without enzyme) maintained 
at 37 ºC was used. The disintegration time in sec was 
recorded as mean±SD of 6 tablets.
In vitro drug release
The in vitro drug release studies of F1, F5, F10 
and a check point batch F11 was conducted in USP 
dissolution testing apparatus II (Paddle type). The 
dissolution fluid is 900 mL of 0.1 N HCl maintained at 
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37±0.5 ºC at an agitational speed of 75 rpm (Riikka, et 
al., 2010; Botzolakis, Small, Augsburger, 1982). Samples 
equal to 2 mL were withdrawn at an interval time of 
1min and up to 7 min, and the concentration was read on 
spectrophotometer at 281 nm.
RESULTS AND DISCUSSION
Compatibility studies
Drug-excipient interactions play a vital role with 
respect to biological performance and stability of the 
formulation. The characteristic absorption peaks obtained 
for drug alone and in presence of polymers (1:1 ratio) are 
depicted in Figure 2. From the spectra, it was observed 
that there were no changes in the main peaks of drug. 
Further, the frequencies of peaks were within the standard 
range, shown in Table II. This indicates that the drug was 
compatible with the selected disintegrants.
Simplex lattice design
The general equation for the response based SLD 
for three components system consisting terms for pure 
component and mixtures of component is
 Y = bo + b1 A + b2 B + b3 C (3)
where, Y is the response variable and A, B and C are the 
proportions of formulation components. The b0 is the 
arithmetic mean response of the 10 runs, and b1, b2 and 
b3 are estimated coefficient for the factor A, B and C 
respectively. The coefficients can be calculated from the 
response (Y) of multiple regression equation. The fitted 
equations relating the hardness, friability, disintegration 
time to the transformed factor are shown in equation 4, 
5, 6 respectively. These polynomial equations were used 
to draw conclusions after considering the magnitude 
of coefficient and the mathematical sign it carries (i.e., 
positive or negative). The contour plot is also presented in 
Figure 3 to graphically represent the effect of independent 
variables on the responses. Table III shows the results of 
the analysis of variance (ANOVA), which was performed 
to identify insignificant factors (Schwartz, 1996).
Effect of independent variables on hardness
The hardness of the formulations were found to 
be between 2.90±0.25 to 3.37±0.05 kg/cm2(Table IV). 
FormulationsF2 and F6 resulted inlower hardness in which 
Polyplasdone XL is a principle disintegrant.This is also 
TABLE II - Frequency of peaks observed in FTIR spectra for nebivolol and its physical mixture with disintegrants
Functional group Nebivolol (cm-1)
Nebivolol and 
PolyplasdoneXL  
(cm-1)
Nebivolol and 
Ac-Di-Sol 
(cm-1)
Nebivolol and 
Primojel 
(cm-1)
O-H aromatic stretch 3444.86 3420.69 3453.62 2900-3600
Aromatic C-H stretch 3040.79 2976.74 2987.12 2922.74
N-H aromatic stretch 3189.30 3197.19 3197.94 3197.07
C-O aromatic stretch 1208.14 1211.66 1211.57 1211.73
FIGURE 2 -FTIR spectra of nebivolol, Polyplasdone XL, Ac-Di-
Sol, Primojel and physical mixture of drug with disintegrants.
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TABLE III - Summary of ANOVA table for dependent variables from simplex lattice design
Source  
(Linear mixture) Sum of squares
Degree of 
freedom Mean square ‘F’ value
Probability 
‘p’ value
Hardness 
Friability 
Disintegration time
0.020 
5.242E-003 
47.30
2 
2 
2
0.010 
2.621E-003 
23.65
2.27 
0.28 
14.69
0.1741 
0.7660 
0.0031*
*p< 0.05 indicate model terms are significant
FIGURE 3 - Response surface plot showing the effect of concentration of Polyplasdone XL, Ac-Di-Sol and Primojel on (a) hardness 
(kg/cm2), (b) friability (%) and (c) disintegration time (Sec).
evident from the polynomial equation for hardness shown 
below. However, the linear model terms for hardness on 
the polynomial equation is appers to be insignificant with 
a ‘F’ value of 2.27 and ‘p’ value of 0.1741 (<0.05).
Y1 (Hardness) = 2.25*A + 2.27*B + 2.41*C (4)
Above polynomial equation infers that concentration 
of factor ‘A’ has less contribution to hardness than B and C 
(Figure 3a). Reason would be that, Polyplasdone particles 
appear to be granular, highly porous and exhibit virtually 
no tendency to undergo binding and compaction (Sunil et 
al., 2007). Whereas tablets made with Primojel (C) and 
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Ac-Di-Sol (B) develops better hardness because of their 
fibrous integrity and optimal degree of substitution in the 
molecule (Komal et al., 2011). These results infers that 
FDT made with Polyplasdone XL alone does not result 
with significant hardness.
Effect of independent variables on friability
The experimental results of friability of all the 
formulations were within 1% limit.
Y2 (Friability) = 0.59*A + 0.57*B + 0.50*C (5)
Equation 5 and Figure 3b indicates that the friability 
is not dependent on any specific variable chosen for the 
study. Also, model terms for friability were found to 
be insignificant on a linear model with a very less ‘F’ 
value (0.28) and higher ‘p’ value (0.766) than the critical 
value (<0.05). This infers that the selected disintegrants 
in the quantities does not promote friability of the 
tablet. However, least friability was observed with the 
formulation which chiefly contains either Ac-Di-Sol (B) 
or Primojel (C) or in combination. Highest friability was 
observed with formulations in which polyplasdone (A) is 
the main ingredient. Hence, it is understood that the use 
of polyplasdone (Parmar Shah, Sheth, 2011) in higher 
percentage may yield a tablet with high % of friability.
Effect of independent variables on disintegration 
time
The experimental results for the disintegration 
time showed a wide variation (Table IV) between the 
formulations. The formulation, which chiefly contains 
Primojel or combination of Primojel and Polyplasdone 
showed lowest disintegration time. This is well evident 
from the polynomial equation shown below.
Y3 (Disintegration time) = 20.74*A + 25.87 *B +  
17.58 *C  (6)
Magnitude of coefficients observed for disintegration 
time indicates that the effect of factor ‘C’ has significant and 
the factor B has insignificant effect on the disintegration 
time. This is also evident from response surface plot 
which indicates higher level of Primojel will decrease the 
disintegration time and the higher level of Ac-Di-Sol will 
increase the disintegration time (Figure 3c).The model 
terms are also significant with a higher ‘F’ value of 14.69 
and ‘p’ value of 0.0031 (<0.05). The reason could be 
that Primojel can take up of water many times its own 
weight and swell powerfully without losing its fibrous 
integrity (Leonardi, 2007). The combination of rapid 
water penetration into tablets through the hydrophilic, 
fibrous particles and the subsequent development of a 
strong disintegration force make Primojel a very effective 
disintegrant (Achor,Oyi, Isah,2010).
Polyplasdone also performs better disintegrating 
action than the Ac-Di-Sol. Porous nature of Polyplasdone 
particles facilitates wicking of liquid into the dosage 
systems and causes rapid disintegration. Due to high 
crosslink density of Polyplasdone, it swells rapidly in 
water without gel formation than others. These properties 
make it a good disintegrant for oral administration 
(Kornblum,Stoopac, 1973).
Disintegration property of Ac-Di-Sol is based on 
TABLE IV - Formulation characteristics
Formulation Hardness (kg/cm2)*
Friability 
(%)
Disintegration 
time (sec)*
Drug content 
(%)
Tablet weight 
(mg)*
Thickness 
(mm)*
F1 2.25±0 .057 0.482 17.16±0.75 95.00 151.12±1.3 3.22± 0.021
F2 2.95 ± 0.22 0.628 21.33±0.51 97.85 149.40±1.0 3.21± 0.024
F3 3.17 ± 0.13 0.468 26.16±0.65 99.28 150.60±0.7 3.21± 0.023
F4 3.22 ± 0.20 0.574 23.03±0.81 96.42 150.40±1.2 3.21± 0.019
F5 3.47 ± 0.15 0.556 25.70±0.75 95.00 150.83±3.15 3.22± 0.022
F6 2.90 ± 0.25 0.672 22.33±0.54 96.42 149.80±1.89 3.21± 0.026
F7 3.42 ± 0.14 0.51 25.33±0.28 97.14 150.20±1.41 3.20±0.022
F8 3.25 ± 0.18 0.50 24.10±0.25 95.71 150.30±1.11 3.20± 0.21
F9 3.37 ± 0.19 0.526 21.16±0.75 97.85 149.90±1.09 3.20± 0.023
F10 3.27 ± 0.24 0.544 26.16± 0.75 98.57 150.50±1.18 3.21± 0.021
*Average of 6 determination ± standard deviation
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TABLE V - Coded quantities of the check point batch “F11” and their desirability
Constraints
Name Goal Lower limit Upper Limit
Hardness 
Friability (%) 
Disintegration time 
Primojel 
Polyplasdone XL 
Ac-Di-Sol
Maximize 
Minimize 
Minimize 
Is in range 
Is in range 
Is in range
3.42±0.14 
0.468 
17.16±0.75 
0 
0 
0
3.47±0.15 
0.628 
23.33±0.28 
1 
1
Solutions (Desirability)
Parameter Primojel Polyplasdone XL Ac-Di-Sol
Hardness (kg/cm2 ) 
Friability (%) 
Disintgration time (sec)  
Check point batch composition
6 
11 
0 
2.5
2.5 
0 
5.5 
3.6
2.5 
0  
5.5 
5.5
*All values are mean of 6 readings ± SD
TABLE VI - Experimented and predicted values of check point batch ‘F11’
Parameter Predicted values Experimented values*
Hardness (kg/cm2) 
Disintegration time (sec) 
Friability % 
3.47±0.15 
17.16±0.75 
0.468
3.85±0.23 
16.38± 2.31 
0.482
powerful water uptake and it takes up more than 20 times 
its own weight of water. Rapid water penetration into the 
tablets and powerful swelling results in rapid disintegration. 
However, Ac-Di-Sol fails to exhibit rapid disintegration 
of the tablet formulation because it exhibits virtually a 
tendency towards gel formation at high ratio. The formation 
of a viscous gel may impede water penetration into the 
tablet which is not favorable for orally disintegrating tablets. 
Hence tablet which chiefly contains Ac-Di-Sol may not 
show fast disintegration (Gohel et al., 2007b).
A checkpoint batch F11 was also prepared (Table V) 
by considering the constraints and with a desirability 
to improve the in vitro performance of the formulation 
F1, F3, and F5 with respect to friability, hardness 
and disintegration time. The experimental results of 
formulation F11 were listed in the Table VI. Predicted 
results were almost similar to the observed experimental 
values indicates the accuracy of the design.
Drug release study
Formulations F1, F3, F5 and F11 were subjected for 
drug release study, have released 90% of drug within 5 min 
and drug release ranged from 93.81±0.73 to 98.58±0.01% 
(Figure 4).Drug release from the formulation F11is most 
satisfactory and it releases 98.58±1.2 of drug in 5 min. This 
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FIGURE 4 - Comparative drug release profile of FDT 
formulations.
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signifies the incorporated disintegrants in the quantities 
doesn’t affect the drug release. Based on above analysis, 
we decided to select formulation F11 as an optimized FDT 
of nebivolol HCl.
CONCLUSIONS
This research work signifies the importance of type and 
proportion of disintigrant in the performance FDT. Judicious 
combination of different disintegrants in a concentration 
may incorporate all the ideal characteristics such as 
optimal hardness, least friability and fast disintegration 
time. Optimal ratio of each disintegrant in the formulation 
can be optimized by adopting a systematic formulation 
approach in the shortest time with minimum efforts using 
SLD. Simplex lattice design could also reduce production 
costs and simplify the formulation process.
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